# The effect of melatonin supplementation on lipid profile, oxidative stress, inflammatory marker, and sleep quality in patients with chronic kidney disease: a GRADE assessed meta-analysis

**Authors:** Qamar Abuhassan, Zahraa Sabah Ghnim, Morug Salih Mahdi, Ashishkumar Kyada, Hamidah Abu Bakar, Neeraj Khare, Dukhbhanjan Singh, Aziz Kubaev, Waam Mohammed Taher, Mariem Alwan, Mahmood Jasem Jawad, Atheer Khdyair Hamad

PMC · DOI: 10.3389/fnut.2026.1772877 · Frontiers in Nutrition · 2026-02-06

## TL;DR

Melatonin improves sleep and reduces oxidative stress in chronic kidney disease patients, but effects on cholesterol are mixed.

## Contribution

A GRADE-assessed meta-analysis of RCTs on melatonin's effects in CKD patients.

## Key findings

- Melatonin increased HDL-C levels in CKD patients.
- Melatonin reduced oxidative stress markers like MDA.
- Melatonin improved sleep quality as measured by PSQI.

## Abstract

Melatonin (MLT) might benefit heart and metabolic health, as well as sleep quality, in individuals with chronic kidney disease (CKD), but the research findings are mixed. To better understand this, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess how MLT affects people with CKD.

Scopus, the Cochrane Library, PubMed, Web of Science, and Embase were searched up to May 30, 2025, for RCTs reporting lipid profiles, oxidative stress markers, or sleep quality. Random-effects meta-analyses were performed, and results are presented as weighted mean differences (WMDs) with 95% confidence intervals (CIs).

Ten RCTs (12 trials) were included. MLT supplementation significantly increased high-density lipoprotein cholesterol (HDL-C: WMD = 1.87 mg/dL, 95% CI: 0.24, 3.50, p = 0.025; I2 = 38.9, p = 0.179), and reduced malondialdehyde (MDA: −1.28 μmol/L, 95% CI: −2.50, −0.06, p = 0.039; I2 = 93.4, p < 0.001), and improved sleep quality (PSQI: WMD = -3.75, 95% CI: −6.92, −0.57, p = 0.021; I2 = 94.2, p < 0.001). Also, MLT supplementation had no significant effect on triglycerides, total cholesterol, low-density lipoprotein cholesterol, or C-reactive protein.

Supplementing with MLT in CKD can gently raise HDL-C levels, decrease oxidative stress, and improve sleep quality. While these effects are encouraging, more extensive and carefully planned clinical trials are necessary to verify the actual benefits.

## Linked entities

- **Chemicals:** melatonin (PubChem CID 896)
- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** obesity (MESH:D009765), kidney damage (MESH:D007674), difficulties falling asleep (MESH:C537863), diabetic nephropathy (MESH:D003928), atherogenic (MESH:D050197), sleep disturbances (MESH:D012893), hypertension (MESH:D006973), dyslipidemia (MESH:D050171), death (MESH:D003643), trauma (MESH:D014947), Inflammatory (MESH:D007249), CKD (MESH:D051436), diabetes (MESH:D003920), HD (MESH:D006816), heart attacks (MESH:D009203), insomnia (MESH:D007319), CVD (MESH:D002318)
- **Chemicals:** lipid (MESH:D008055), reactive oxygen species (MESH:D017382), glucose (MESH:D005947), cholesterol (MESH:D002784), CD (MESH:D002104), TC (MESH:D013667), MLT (MESH:D008550), HDL-C (-), malondialdehyde (MESH:D008315), TG (MESH:D014280), MDA (MESH:D015104)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920205/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920205/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920205/full.md

---
Source: https://tomesphere.com/paper/PMC12920205